Novavax (NVAX) vs Sarepta Therapeutics (SRPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Novavax (NVAX) has outperformed Sarepta Therapeutics (SRPT) over the past year, gaining 23.7% versus a loss of 22.1%. Over five years, SRPT leads with a -79.2% price change compared with -93.1% for NVAX. Sarepta Therapeutics is the larger company by market cap ($1.92 billion vs $1.82 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVAX | SRPT |
|---|---|---|
| Share price | $11.01 | $18.21 |
| Market cap | $1.82B | $1.92B |
| 1-day change | -1.87% | +4.06% |
| YTD return | +63.84% | -15.38% |
| 1-year return | +23.71% | -22.11% |
| 5-year return | -93.07% | -79.21% |
| Forward P/E | — | 7.55 |
| EPS (TTM) | $-1.58 | $-1.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.39 | $24.68 |
| 52-week low | $6.20 | $14.68 |
| Distance from 52-week high | -17.77% | -26.22% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +27.16% | +19.33% |
| Average volume | 5.16M | 2.98M |
| Shares outstanding | 164.95M | 105.63M |
| Employees | 749 | 835 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVAX has outperformed SRPT by 45.8 percentage points over the past year.
About Novavax
NVAX stock →Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
NVAX vs SRPT FAQ
Which is bigger, Novavax or Sarepta Therapeutics?
Sarepta Therapeutics (SRPT) is larger, with a market capitalization of $1.92B compared with $1.82B for Novavax (NVAX).
Which stock has performed better over the past year, NVAX or SRPT?
NVAX returned +23.71% over the past 12 months, compared with -22.11% for SRPT (price return, excluding dividends). Past performance does not predict future results.
Are Novavax and Sarepta Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Novavax and Biotechnology: Pharmaceutical Preparations for Sarepta Therapeutics.